The use case for a low-cost, highly accessible SARS-CoV-2 test is strong even if the test were to be less sensitive than current RT-PCR testing. Modeling shows that decentralized, point-of-care testing with rapid return of results would have greater potential impact on transmission than the absolute limit-ofdetection of the test. These models build on the important observation that infectious viral particles have not been recovered below around 100 copies/mL. Rapid analyte tests are beginning to enter the commercial market. Thus far, however, few analyte tests for SARS-CoV-2, compared to nucleic acid tests, have received authorization from regulatory authorities worldwide. Therefore, a concerted effort is underway to catalyze the development of analyte-based rapid diagnostic tests that require no or minimal instrumentation, and to prepare manufacturing capability to meet the needs of the larger global market. Required performance characteristics of a SARS-CoV-2 analyte detection assay have been published by the World Health Organization. A key step in the development of an LFA is the selection of selective antibodies for the target of interest. To expedite this process, our group has pioneered a high-throughput, robotic, antibodyscreening process directly on nitrocellulose. This method allows us to rapidly screen hundreds of combinations of antibodies more quickly than is typical of early-stage LFA development, while simultaneously utilizing nitrocellulose-specific reaction kinetics and flow rates that are difficult-toimpossible to mimic in other multiplexed analytical systems (e.g., ELISA, biolayer interferometry). Chemical gradients, residence times, binding orientations, affinity rates, drying and subsequent rehydration of reagents, and spatial distributions of antibodies are different in LFAs than in other immunoassays, and therefore, the best antibodies for LFAs may be different than for the best antibodies for ELISA, for example.